EUVIMEDEUVIMED entdecken
Crossref

ETS Translocation Variant 5 Negatively Modulates Innate Immunity to Facilitate Epstein‐Barr Virus Reactivation

Xuefei Liao, Mengdi Chen, Li Yang, Mingjuan Jiang, Yujie Xin, Huirong Yan, Qingshuang Qin, Jianhong Lu iD

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.70783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Xuefei Liao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Immunity, Innate, Herpesvirus 4, Human, Virus Activation, Epstein-Barr Virus Infections. Die Arbeit nennt 42 Literaturangaben. Gefördert von: The National Natural Science Foundations of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein‐Barr virus (EBV) is a member of the gamma‐herpesvirus subfamily that is prevalent in the human population. There are two phases of EBV infection: latent infection and lytic infection. During lytic reactivation, host innate immune responses are activated to restrict EBV replication. Here, we identified ETS translocation variant 5 (ETV5) as a negative regulator of innate immune responses to facilitate EBV reactivation. ETV5 expression was upregulated by the EBNA1/BRD7 axis, which had been previously described by us, during EBV latent infection. When EBV was induced into lytic replication, the expression of ETV5 was further increased, and ETV5 overexpression dramatically enhanced the lytic replication of EBV. Mechanistically, upon EBV reactivation, the overexpression of ETV5 suppressed the activation of TANK‐binding kinase 1 and interferon regulatory factor 3 (IRF3), as well as the transcription of interferon beta (IFNB1) gene and interferon‐stimulated genes (ISGs). The effect of ETV5 knockdown could be reversed by an inhibitor of innate immunity pathway. These findings position ETV5 as a critical accelerator of EBV reactivation through immune evasion, revealing new therapeutic targets for managing EBV‐associated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, InnateHerpesvirus 4, HumanVirus ActivationEpstein-Barr Virus InfectionsTranscription FactorsDNA-Binding ProteinsHumansVirus ReplicationVirus LatencyHost-Pathogen Interactions

Stichwörter der Autor:innen

ETV5Epstein‐Barr virusinnate immune responsereactivation

Substanzen

Transcription FactorsDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Microbiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
  • NHC Key Laboratory of Carcinogenesis, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.
  • Department of Microbiology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, China.

ORCID-Profile: Jianhong Lu

Förderung

  • The National Natural Science Foundations of China

Zitieren

APA

Liao, X., Chen, M., Yang, L., Jiang, M., Xin, Y., Yan, H., Qin, Q., & Lu, J. (2026). ETS Translocation Variant 5 Negatively Modulates Innate Immunity to Facilitate Epstein‐Barr Virus Reactivation. Journal of Medical Virology. https://doi.org/10.1002/jmv.70783

Vancouver

Liao X, Chen M, Yang L, Jiang M, Xin Y, Yan H, et al. ETS Translocation Variant 5 Negatively Modulates Innate Immunity to Facilitate Epstein‐Barr Virus Reactivation. Journal of Medical Virology. 2026. doi:10.1002/jmv.70783

BibTeX
@article{Liao2026,
  author = {Liao, Xuefei and Chen, Mengdi and Yang, Li and Jiang, Mingjuan and Xin, Yujie and Yan, Huirong and Qin, Qingshuang and Lu, Jianhong},
  title = {ETS Translocation Variant 5 Negatively Modulates Innate Immunity to Facilitate Epstein‐Barr Virus Reactivation},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.70783}
}
Kostenlos starten →